These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 17527087)
1. Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Delahunt B; Sika-Paotonu D; Bethwaite PB; McCredie MR; Martignoni G; Eble JN; Jordan TW Am J Surg Pathol; 2007 Jun; 31(6):957-60. PubMed ID: 17527087 [TBL] [Abstract][Full Text] [Related]
2. Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Sika-Paotonu D; Bethwaite PB; McCredie MR; William Jordan T; Delahunt B Am J Surg Pathol; 2006 Sep; 30(9):1091-6. PubMed ID: 16931953 [TBL] [Abstract][Full Text] [Related]
3. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Delahunt B; Sika-Paotonu D; Bethwaite PB; William Jordan T; Magi-Galluzzi C; Zhou M; Samaratunga H; Srigley JR Am J Surg Pathol; 2011 Aug; 35(8):1134-9. PubMed ID: 21716085 [TBL] [Abstract][Full Text] [Related]
4. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Paner GP; Amin MB; Alvarado-Cabrero I; Young AN; Stricker HJ; Moch H; Lyles RH Am J Surg Pathol; 2010 Sep; 34(9):1233-40. PubMed ID: 20679882 [TBL] [Abstract][Full Text] [Related]
5. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. Finley DS; Shuch B; Said JW; Galliano G; Jeffries RA; Afifi AA; Castor B; Magyar C; Sadaat A; Kabbinavar FF; Belldegrun AS; Pantuck AJ J Urol; 2011 Dec; 186(6):2168-74. PubMed ID: 22014797 [TBL] [Abstract][Full Text] [Related]
6. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Gudbjartsson T; Hardarson S; Petursdottir V; Thoroddsen A; Magnusson J; Einarsson GV Eur Urol; 2005 Oct; 48(4):593-600. PubMed ID: 15964127 [TBL] [Abstract][Full Text] [Related]
7. Percentage of high-grade carcinoma as a prognostic indicator in patients with renal cell carcinoma. Serrano MF; Katz M; Yan Y; Kibel AS; Humphrey PA Cancer; 2008 Aug; 113(3):477-83. PubMed ID: 18484589 [TBL] [Abstract][Full Text] [Related]
8. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Ficarra V; Martignoni G; Maffei N; Brunelli M; Novara G; Zanolla L; Pea M; Artibani W Cancer; 2005 Jan; 103(1):68-75. PubMed ID: 15573369 [TBL] [Abstract][Full Text] [Related]
9. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: Assessment of 241 patients with > 15-year follow-up. Lang H; Lindner V; de Fromont M; Molinié V; Letourneux H; Meyer N; Martin M; Jacqmin D Cancer; 2005 Feb; 103(3):625-9. PubMed ID: 15611969 [TBL] [Abstract][Full Text] [Related]
10. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Amin MB; Paner GP; Alvarado-Cabrero I; Young AN; Stricker HJ; Lyles RH; Moch H Am J Surg Pathol; 2008 Dec; 32(12):1822-34. PubMed ID: 18813125 [TBL] [Abstract][Full Text] [Related]
11. Chromophobe renal cell carcinoma: the impact of tumor grade on outcome. Cheville JC; Lohse CM; Sukov WR; Thompson RH; Leibovich BC Am J Surg Pathol; 2012 Jun; 36(6):851-6. PubMed ID: 22367296 [TBL] [Abstract][Full Text] [Related]
12. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. Verhoest G; Avakian R; Bensalah K; Thuret R; Ficarra V; Artibani W; Tostain J; Guille F; Cindolo L; De La Taille A; Abbou CC; Salomon L; Rioux-Leclercq N; Patard JJ J Urol; 2009 Sep; 182(3):854-9. PubMed ID: 19616244 [TBL] [Abstract][Full Text] [Related]
14. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Delahunt B; Eble JN; McCredie MR; Bethwaite PB; Stewart JH; Bilous AM Hum Pathol; 2001 Jun; 32(6):590-5. PubMed ID: 11431713 [TBL] [Abstract][Full Text] [Related]
15. Collecting system invasion and Fuhrman grade but not tumor size facilitate prognostic stratification of patients with pT2 renal cell carcinoma. Brookman-May S; May M; Zigeuner R; Shariat SF; Scherr DS; Chromecki T; Moch H; Wild PJ; Mohamad-Al-Ali B; Cindolo L; Wieland WF; Schips L; De Cobelli O; Rocco B; Santoro L; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Dalpiaz O; Hohenfellner M; Gilfrich C; Wirth MP; Burger M; Pahernik S; J Urol; 2011 Dec; 186(6):2175-81. PubMed ID: 22014800 [TBL] [Abstract][Full Text] [Related]
16. Significance of nuclear grade and tumor size in Korean patients with chromophobe renal cell carcinoma: a comparison with conventional renal cell carcinoma. Ku JH; Moon KC; Kwak C; Kim HH Urol Oncol; 2011; 29(5):487-91. PubMed ID: 19767221 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of primary-tumor extension, stage and grade of nuclear differentiation in patients with renal cell carcinoma. Fiori E; De Cesare A; Galati G; Bononi M; D'Andrea N; Barbarosos A; Izzo L; Bolognese A J Exp Clin Cancer Res; 2002 Jun; 21(2):229-32. PubMed ID: 12148583 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. Yoo C; Song C; Hong JH; Kim CS; Ahn H J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101 [TBL] [Abstract][Full Text] [Related]
19. Intraobserver and interobserver variability of Fuhrman and modified Fuhrman grading systems for conventional renal cell carcinoma. Bektas S; Bahadir B; Kandemir NO; Barut F; Gul AE; Ozdamar SO Kaohsiung J Med Sci; 2009 Nov; 25(11):596-600. PubMed ID: 19858038 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. Patard JJ; Leray E; Rioux-Leclercq N; Cindolo L; Ficarra V; Zisman A; De La Taille A; Tostain J; Artibani W; Abbou CC; Lobel B; Guillé F; Chopin DK; Mulders PF; Wood CG; Swanson DA; Figlin RA; Belldegrun AS; Pantuck AJ J Clin Oncol; 2005 Apr; 23(12):2763-71. PubMed ID: 15837991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]